Market Cap 611.07B
Revenue (ttm) 94.19B
Net Income (ttm) 26.80B
EPS (ttm) N/A
PE Ratio 24.02
Forward PE 22.26
Profit Margin 28.46%
Debt to Equity Ratio 0.46
Volume 5,148,280
Avg Vol 8,216,500
Day's Range N/A - N/A
Shares Out 2.41B
Stochastic %K 4%
Beta 0.24
Analysts Strong Sell
Price Target $265.44

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 732 524 0400
Website: www.jnj.com
Address:
One Johnson & Johnson Plaza, New Brunswick, United States
TheStockTraderHub
TheStockTraderHub Jul. 16 at 5:46 PM
$JNJ SEEING $1M CALL BUYER INTO THIS ROTATION 👀
0 · Reply
WallStJesus
WallStJesus Jul. 16 at 5:44 PM
$JNJ Put/Call: 3702/18k
0 · Reply
SpudZone
SpudZone Jul. 16 at 4:52 PM
$BMY Dividend name and compounder been holding for years, finally having a great couple weeks. Looking for more action while dividend yield pays out nicely. $JNJ has been sneaky on fire while AI stalls.
0 · Reply
dontebosley
dontebosley Jul. 16 at 4:40 PM
$JNJ floating in green amongst chaos like it always does
0 · Reply
Biotech80
Biotech80 Jul. 16 at 4:22 PM
$LEGN Always after $JNJ earnings with Cart-T readout drops like a stone, looking to re-enter as easily a $35 - $40 dollar stock by Q4 - set a buy of 200k at $18.49 if it gets there will be a minimum 75-100% returns within 99 days 💰
0 · Reply
NodeNebula
NodeNebula Jul. 16 at 4:14 PM
$JNJ’s Spravato continues to gain momentum as interest in psychedelic-based depression treatments grows. While competitors like Compass Pathways’ $CMPS COMP360 are advancing in the space, analysts believe they are unlikely to create an immediate threat to Spravato’s current sales trajectory. The bigger picture is that the depression treatment market is expanding, but adoption, regulatory approval, and real-world delivery will determine how quickly next-generation therapies can challenge established players.
0 · Reply
IN0V8
IN0V8 Jul. 16 at 2:52 PM
$JNJ Bernstein raises target price to $261 from $251 Leerink Partners raises target price to $276 from $265 Morgan Stanley raises target price to $294 from $284 Raymond James raises target price to $265 from $258 Wells Fargo raises target price to $272 from $263
0 · Reply
Wallstfan
Wallstfan Jul. 16 at 2:47 PM
$MCD and $JNJ great safe plays with the tech decline
0 · Reply
BarkingPuppy
BarkingPuppy Jul. 16 at 2:28 PM
$PFE $JNJ $LLY #$MRNA Do you vote for ELTP???? Big News Coming.
0 · Reply
TraderDaKing
TraderDaKing Jul. 16 at 1:41 PM
$ELTP $TSLA $JNJ $AMC $DJT Elite Pharma .... ELTP Stock Buyout or Merger??? lots a talk about ELTP...
0 · Reply
Latest News on JNJ
DePuy Synthes Acquires Expanding Innovations™

Jul 16, 2026, 8:00 AM EDT - 6 hours ago

DePuy Synthes Acquires Expanding Innovations™


Johnson & Johnson Earnings Call Transcript: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 1 day ago

Johnson & Johnson Earnings Call Transcript: Q2 2026


Johnson & Johnson Slides: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 1 day ago

Johnson & Johnson Slides: Q2 2026


Johnson & Johnson Earnings release: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 1 day ago

Johnson & Johnson Earnings release: Q2 2026


Johnson & Johnson Hikes Guidance, Stock Falls

Jul 15, 2026, 6:35 AM EDT - 1 day ago

Johnson & Johnson Hikes Guidance, Stock Falls


Johnson & Johnson Bumps Up Guidance as Sales Rise

Jul 15, 2026, 6:33 AM EDT - 1 day ago

Johnson & Johnson Bumps Up Guidance as Sales Rise


The Big 3: UNH, KO, JNJ

Jul 9, 2026, 1:00 PM EDT - 7 days ago

The Big 3: UNH, KO, JNJ

KO UNH


Johnson & Johnson to Buy Firefly Bio for $1 Billion

Jun 8, 2026, 9:01 AM EDT - 5 weeks ago

Johnson & Johnson to Buy Firefly Bio for $1 Billion


Johnson & Johnson to buy Firefly Bio for $1 billion

Jun 8, 2026, 8:08 AM EDT - 5 weeks ago

Johnson & Johnson to buy Firefly Bio for $1 billion


Johnson & Johnson says nipocalimab approved in China

May 21, 2026, 4:31 AM EDT - 2 months ago

Johnson & Johnson says nipocalimab approved in China


CVS to drop J&J's Stelara from its main formularies

May 5, 2026, 9:15 AM EDT - 2 months ago

CVS to drop J&J's Stelara from its main formularies

CVS


TheStockTraderHub
TheStockTraderHub Jul. 16 at 5:46 PM
$JNJ SEEING $1M CALL BUYER INTO THIS ROTATION 👀
0 · Reply
WallStJesus
WallStJesus Jul. 16 at 5:44 PM
$JNJ Put/Call: 3702/18k
0 · Reply
SpudZone
SpudZone Jul. 16 at 4:52 PM
$BMY Dividend name and compounder been holding for years, finally having a great couple weeks. Looking for more action while dividend yield pays out nicely. $JNJ has been sneaky on fire while AI stalls.
0 · Reply
dontebosley
dontebosley Jul. 16 at 4:40 PM
$JNJ floating in green amongst chaos like it always does
0 · Reply
Biotech80
Biotech80 Jul. 16 at 4:22 PM
$LEGN Always after $JNJ earnings with Cart-T readout drops like a stone, looking to re-enter as easily a $35 - $40 dollar stock by Q4 - set a buy of 200k at $18.49 if it gets there will be a minimum 75-100% returns within 99 days 💰
0 · Reply
NodeNebula
NodeNebula Jul. 16 at 4:14 PM
$JNJ’s Spravato continues to gain momentum as interest in psychedelic-based depression treatments grows. While competitors like Compass Pathways’ $CMPS COMP360 are advancing in the space, analysts believe they are unlikely to create an immediate threat to Spravato’s current sales trajectory. The bigger picture is that the depression treatment market is expanding, but adoption, regulatory approval, and real-world delivery will determine how quickly next-generation therapies can challenge established players.
0 · Reply
IN0V8
IN0V8 Jul. 16 at 2:52 PM
$JNJ Bernstein raises target price to $261 from $251 Leerink Partners raises target price to $276 from $265 Morgan Stanley raises target price to $294 from $284 Raymond James raises target price to $265 from $258 Wells Fargo raises target price to $272 from $263
0 · Reply
Wallstfan
Wallstfan Jul. 16 at 2:47 PM
$MCD and $JNJ great safe plays with the tech decline
0 · Reply
BarkingPuppy
BarkingPuppy Jul. 16 at 2:28 PM
$PFE $JNJ $LLY #$MRNA Do you vote for ELTP???? Big News Coming.
0 · Reply
TraderDaKing
TraderDaKing Jul. 16 at 1:41 PM
$ELTP $TSLA $JNJ $AMC $DJT Elite Pharma .... ELTP Stock Buyout or Merger??? lots a talk about ELTP...
0 · Reply
BarkingPuppy
BarkingPuppy Jul. 16 at 1:34 PM
$ELTP $KO $JNJ $AMC $SPACX Go Vote on ELTP ( Elite ) Thank You. Your Vote is needed.
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jul. 16 at 12:14 PM
$JNJ $SLS Part 2. 2026 WSJ CEO council summit - 6/15/26 JNJ CEO on curing cancer or turning cancer into a chronic disease, especially in hematology. Strikingly similar to what Dr.Stergiou said in one of his Linkein posts on GPS turning AML into a curative disease. BO bidding $40B $JNJ, AbbVie Merck, Roche. ✌️🙏❤️‍🩹
0 · Reply
spearnreel
spearnreel Jul. 16 at 12:11 PM
$BSX Med tech showing life today off heels of $ABT reporting. $JNJ forecasting to hit $100 bil annual revs 2026, first in history. Frothy tech and specs showing weakness and should lead to reallocation here imo. Analysts completed their tasks in beating down the sector with constant PT revisions all the while maintaining buy recommendations. This is typically the recipe for real reversal and we can star in this show starting today if we want it. $MDT $ISRG
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jul. 16 at 11:58 AM
$SLS $JNJ JNJ said it aims to become the world's No. 1 oncology company by 2030 with over $50 billion in sales. Big Pharma's next oncology target after Johnson & Johnson doubled down on acquisitions and its goal of becoming the world's No. 1 cancer-drug company. $SLS Next up. $SLS BOD Katherine Bach that bought shares on open market twice last year was also a Johnson & Johnson VP of Franchise Strategic Management for 10 years. She then worked atCelgene as a VP of Corporate Strategy for 5 years before Bristol-Myers acquired them for $74B. ✌️🙏❤️‍🩹
1 · Reply
outlawinvestor1
outlawinvestor1 Jul. 16 at 11:12 AM
0 · Reply
Petersen73
Petersen73 Jul. 16 at 8:09 AM
0 · Reply
WolfOfWillowick
WolfOfWillowick Jul. 16 at 8:01 AM
0 · Reply
StocktwitsNews
StocktwitsNews Jul. 16 at 7:12 AM
SLS, IBRX Rise Overnight: Retail Bets On Big Pharma Buyouts As J&J Chases No. 1 Oncology Spot $SLS $IBRX $JNJ https://stocktwits.com/news/equity/markets/sls-ibrx-retail-big-pharma-buyouts-jnj-no1-oncology-spot/cZZEcThR7rH
1 · Reply
leLu83
leLu83 Jul. 16 at 1:03 AM
$ATAI we just bat signaled the entire pharma sector 💯 Johnson & Johnson ($JNJ) is the biggest wildcard in this scenario. Their blockbuster psychiatric drug Spravato (esketamine) is currently pacing toward multi-billion-dollar annual revenues. ​The Threat: BPL-003 represents a massive, direct threat to Spravato because it boasts a 90-minute in-clinic monitoring window compared to Spravato's rigid 2-hour requirement. ​The Action: J&J has a massive balance sheet and a strong defensive incentive to overbid Eli Lilly to keep BPL-003 out of a competitor's hands—or to capture the next-generation market leader themselves.
2 · Reply
leLu83
leLu83 Jul. 16 at 12:58 AM
$ATAI JnJ should really make an offer bc Lilly will completely destroy spravato soon in clinics. They have cash. They should moat their leading growth blockbuster drug. Lilly looking to dominate short acting CNS psychs. JnJ going to let it slip? $JNJ
0 · Reply
Millionaire11
Millionaire11 Jul. 16 at 12:36 AM
$CMPS this has became real very fast $JNJ and others are going to want to jump in quick or $LLY is going to be only of the few big pharma companies with access to this new class of mental health drugs.
1 · Reply
Millionaire11
Millionaire11 Jul. 15 at 10:59 PM
$CMPS - $ATAI buy out from $LLY that means $JNJ could still be eying $CMPS. Lets hope for a massive buy out price of 10 billion plus. That would be massive for the whole industry. Good luck every body and trust the process.
1 · Reply